Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
- Fixed-dose combination of ASC36 and ASC35 (ASC36_35 FDC) demonstrated superior weight loss compared to eloralintide in combination with tirzepatide in a diet-induced obese (DIO) animal model. HONG KONG, July 23, 2026 /PRNewswire/ -- Ascletis...
AI-Powered Connectivity: APAC Charts a Path to a Smarter Digital Future
Asia-Pacific's first Broadband Development Summit brings regulators and operators to Bangkok to set the agenda BANGKOK, July 19, 2026 /PRNewswire/ -- Government officials, standards bodies and telecom operators gathered in Bangkok on 14 July for the...
HKSH's First-in-Asia Comparative Study on Radiotherapy for Breast Cancer Reveals Hypofractionated Proton Therapy Prevents Breast Cancer Recurrence with 100% Survival Rate
Minimises Cardiopulmonary Concerns and Maintains Quality of Life HONG KONG, July 7, 2026 /PRNewswire/ -- The HKSH Cancer Centre under HKSH Medical Group (HKSH) introduced proton therapy in 2023, covering a wide range of cancer types including...
69 ESG Champions Recognized at the Asia Responsible Enterprise Awards (AREA) 2026 for Shaping a Regenerative and Inclusive Tomorrow
KUALA LUMPUR, Malaysia, July 2, 2026 /PRNewswire/ -- The Asia Responsible Enterprise Awards (AREA) 2026 honored 69 outstanding ESG champions for leveraging innovation, digital transformation, and responsible business practices to drive sustainable...
NextRise 2026, Seoul Successfully Wraps Up as Asia's Leading Startup Fair Co-hosted by KITA and KDB
SEOUL, South Korea, June 26, 2026 /PRNewswire/ -- The Korea International Trade Association (KITA) and Korea Development Bank (KDB) successfully wrapped up NextRise 2026, Seoul, Asia's leading startup fair, at COEX in Samseong-dong, Seoul, after a...
Avinox Unveils the Avinox MG Concept Product at Eurobike 2026
Developed in collaboration with Canyon, Commencal, Forbidden, Mondraker, and Megamo FRANKFURT, Germany, June 24, 2026 /PRNewswire/ -- Avinox, the e-bike systems company building integrated technology to power the next generation of electric...
Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026
HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) were presented...
Over a Thousand Developers Pursue the Dream of Open Computing! FlagOS Open Computing Global Challenge Season 1 Award Ceremony Featured at the 8th BAAI Conference
BEIJING, June 16, 2026 /PRNewswire/ -- On June 13, the award ceremony for the FlagOS Open Computing Global Challenge (Season 1), jointly organized by the Beijing Academy of Artificial Intelligence (BAAI) and the FlagOS Community, was held during the...
ACON OPTICS (TWSE: 6820) Strengthens AI High-Speed Interconnect Portfolio with CPO and 1.6T Connectivity Technologies at COMPUTEX 2026
TAIPEI, June 16, 2026 /PRNewswire/ -- ACON OPTICS (TWSE: 6820), a leading provider of advanced optical connectivity solutions, showcased its latest innovations in AI optical interconnect technologies at COMPUTEX 2026 under the theme "Shaping...
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. Post-hoc...